Trending...
- Long Beach Parks, Recreation and Marine to Update Operating Hours and Programming at City Gyms
- Twitch Streamer Caiuwus Emerges From "Streamer University" Spotlight With New Ambitions for 2026
- Fabian Starr Announces "Back to the Arcade" Remix Album
SUNNYVALE, Calif., Sept. 14, 2021 /PRNewswire/ -- Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert Xpress CoV-2/Flu/RSV plus, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and respiratory syncytial virus (RSV) infections from a single patient sample. The new plus version of the test provides a third gene target for SARS-CoV-2 detection to meet the challenge of future viral mutations. Xpert Xpress CoV-2/Flu/RSV plus is designed for use on any of Cepheid's over 35,000 GeneXpert® Systems placed worldwide, with results delivered in approximately 36 minutes.
Multiple variants of the virus that causes COVID-19 have been documented globally during the pandemic. Viruses constantly change through mutation, and new variants of a virus are expected to occur over time. Adding a 3rd gene target to the plus version of Cepheid's CoV-2/Flu/RSV test delivers broader coverage to mitigate the possible effects of future viral genetic drift.
"This respiratory season, healthcare providers may encounter a range of viral infections with symptoms that overlap with COVID-19, including Flu A, Flu B, and respiratory syncytial virus. Having a fast and accurate test that is designed to detect current and future variants of the viruses that cause COVID-19 and influenza will become increasingly important," said Dr. David Persing, MD, Ph.D., Chief Medical and Technology Officer at Cepheid. "The ability to collect one sample and run a single, highly-sensitive multiplexed test that detects and differentiates all four viruses will provide actionable results to inform better front-line decisions within our healthcare systems."
More on The Californer
Xpert Xpress CoV-2/Flu/RSV plus is expected to begin shipping to US customers in the next few weeks.
Visit www.cepheid.com for more information, videos, and package inserts.
About Cepheid
Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated molecular diagnostic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.
About Emergency Use Authorization Status
More on The Californer
This test has not been FDA cleared or approved. It has been authorized by the FDA under an EUA for use by authorized laboratories. The test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus, and RSV and not for any other viruses or pathogens. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
For Cepheid Media Inquiries:
Darwa Peterson
[email protected]
SOURCE Cepheid
Multiple variants of the virus that causes COVID-19 have been documented globally during the pandemic. Viruses constantly change through mutation, and new variants of a virus are expected to occur over time. Adding a 3rd gene target to the plus version of Cepheid's CoV-2/Flu/RSV test delivers broader coverage to mitigate the possible effects of future viral genetic drift.
"This respiratory season, healthcare providers may encounter a range of viral infections with symptoms that overlap with COVID-19, including Flu A, Flu B, and respiratory syncytial virus. Having a fast and accurate test that is designed to detect current and future variants of the viruses that cause COVID-19 and influenza will become increasingly important," said Dr. David Persing, MD, Ph.D., Chief Medical and Technology Officer at Cepheid. "The ability to collect one sample and run a single, highly-sensitive multiplexed test that detects and differentiates all four viruses will provide actionable results to inform better front-line decisions within our healthcare systems."
More on The Californer
- California: Governor Newsom proclaims Nowruz
- California announces 300 wildfire projects fast-tracked in 300 days
- Women Lead the Way at America's Longest Running Reggae Festival
- Cleverly Using Tax Refunds to Purchase Eyeglasses
- Inkdnylon Custom Apparel Launches Cost-Saving System for Promotional Products and Custom Apparel in Chicago
Xpert Xpress CoV-2/Flu/RSV plus is expected to begin shipping to US customers in the next few weeks.
Visit www.cepheid.com for more information, videos, and package inserts.
About Cepheid
Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated molecular diagnostic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.
About Emergency Use Authorization Status
More on The Californer
- ENTOUCH Named Finalist for 2026 North American Inspiring Workplaces Awards
- Cleveland County Goat Farm NC Kikos Featured in "Feature Farmer Friday" Documentary
- San Diego Ranked #2 Worst Allergy City - ATO Health Sinus Rinse Offers Drug-Free Relief
- Tony Grundler Introduces Artificial Intelligence V.S. Avatar-Ian's
- Bay Area Startup Permitio.ai Launches AI Agent for HVAC Permits
This test has not been FDA cleared or approved. It has been authorized by the FDA under an EUA for use by authorized laboratories. The test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus, and RSV and not for any other viruses or pathogens. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
For Cepheid Media Inquiries:
Darwa Peterson
[email protected]
SOURCE Cepheid
Filed Under: Business
0 Comments
Latest on The Californer
- U.S. Government Contracts in Excess of 38 Million Secured Through Partner, Establishing Multi-Year Defense Revenue Platform Through 2032: $BLIS
- New Report Reveals Surprising Trends in Ohio Airport Accidents
- Why Your Berberine Failed: RevGenetics Unveils the Absorption Gap Solution
- WCC Kitchens and Cabinets Featured on Selling Houses Australia
- Best Fish Oil Supplement for Cholesterol Gains Attention from Fun And Easy Health Company
- Cat Hunt Simulator : Burrow & Pounce Lands on the App Store
- Shincheonji Marks 42nd Anniversary: From a Basement to a Denomination Growing by Tens of Thousands Annually
- California: El Gobernador Newsom amplía la educación financiera en las escuelas y el acceso a la creación de riqueza para las mujeres.
- Jackets for Jobs Hosts Smart & Sexy® Day Detroit for Women's History Month
- JetVoy Advances as a Coordination Layer for Global Mobility and Exclusive Access
- Long Beach Public Works to Host Community Meeting on the Pacific Avenue Transformation Project
- California Homeowners Turn to PODS® to Navigate Competitive Spring Real Estate Market
- San Diego Diesel Drivers Turn to Santee Repair Shop as Demand for Heavy-Duty Vehicle Service Grows
- Saphira AI Joins NVIDIA Halos AI Systems Inspection Lab to Advance AI for Autonomous Systems
- Wordly to Provide AI Translation for all 2026 Association of National Olympic Committees Events
- ATO Health 100 Sinus Rinse Packets Offer Natural Relief as hMPV Virus Triggers Record Nasal Congestion Cases
- Snell & Wilmer Recognized Among the Top 10 Largest Law Firms in Orange County by the OCBJ
- Stockdale Capital Announces Four New Major Hires
- California: Governor Newsom announces next round of television tax credits, adding animated and competition shows for the first time
- As AI Accelerates Software Delivery, ThinkSys Introduces Zero Critical Bugs Guarantee